A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

Recruiting now · Phase 1

Conditions studied: Solid Tumor

In brief

The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.

Key facts

Study ID

NCT07275242

Run by

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

People needed

107

Starts

2025-12-23

Expected to finish

2027-12-01

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age;
• Solid Tumor confirmed by histology or cytology;
• ECOG score is 0 or 1;
• An expected survival of ≥ 12 weeks;
• At least one measurable lesion according to RECIST v1.1 criteria;
• Have adequate renal and hepatic function;
• Patients voluntarily joined the study and signed informed consent.

You may not qualify if…

• With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer;
• Patients have major surgical procedures or radiotherapy / chemotherapy within 4 weeks before the first medication;
• History of immunodeficiency;
• Clinically significant cardiovascular diseases;
• Known or suspected interstitial lung disease;
• Known hereditary or acquired bleeding thrombotic tendency;
• Active hepatitis and liver cirrhosis;
• Known allergic history of the drug components of this protocol;
• History of neurological or psychiatric disorders.

Where it is running

• Sun Yat-sen Memorial Hospital, Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.